中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 6
Jun.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(6): 1307-1310

Value of serum IgG4 level in differential diagnosis of IgG4-related pancreatic and hepatobiliary diseases and non-IgG4-related pancreatic and hepatobiliary diseases

DOI: 10.3969/j.issn.1001-5256.2022.06.017
  • 1.

    Department of Clinical Laboratory, Huai'an No. 1 People's Hospital Affiliated to Nanjing Medical University, Huai'an, Jiangsu 223300, China

  • 2.

    Department of Clinical Laboratory, Xuzhou First People's Hospital, Xuzhou, Jiangsu 221000, China

  • 3.

    Department of Clinical Laboratory, Subei People's Hospital, Yangzhou, Jiangsu 225000, China

  • 4.

    Jiangsu College of Nursing, Huai'an, Jiangsu 223300, China

Research funding:

Huai'an City Innovation Service Capacity and Key Laboratory Construction Building Plan (HAP202004)

More Information
  • Corresponding author: JIANG Yuzhang, jyz8848@163.com (ORCID:0000-0002-8544-9485)
  • Received Date: 2021-10-01
  • Accepted Date: 2021-11-23
  • Published Date: 2022-06-20
    Abstract
  •   Objective  To investigate the value of serum IgG4 level in the differential diagnosis of IgG4-related pancreatic and hepatobiliary disease (IgG4-PHD) and non-IgG4-related disease (non-IgG4-RD).  Methods  Clinical data were collected from 491 patients who were hospitalized and 50 individuals who underwent physical examination in Huaian No. 1 People's Hospital Affiliated to Nanjing Medical University, Subei People's Hospital, and The First Affiliated Hospital of Xuzhou Medical University from August 2014 to April 2021. The 491 patients were divided into IgG4-PHD group with 20 patients, non-IgG4-RD autoimmune disease group with 431 patients (104 patients with systemic lupus erythematosus, 79 with rheumatoid arthritis, 174 with Sjogren's syndrome, 16 with ankylosing spondylitis, 11 with scleroderma, 4 with adult-onset Still's disease, 30 with myositis, 3 with psoriasis, and 10 with primary sclerosing cholangitis), and malignant pancreatic/hepatobiliary tumor group with 40 patients, and the 50 individuals undergoing physical examination were enrolled as healthy control group. Scattering immunoturbidimetric assay was used to measure serum IgG4 concentration. The two-sample Mann-Whitney U test was used for comparison of normally distributed continuous data between groups, and the Fisher's exact test was used for comparison of categorical data between groups. The receiver operating characteristic (ROC) curve was plotted to determine the optimal cut-off value of serum IgG4 in the diagnosis of IgG4-PHD.  Results  The IgG4-PHD group had a significantly higher serum IgG4 level than the non-IgG4-RD autoimmune disease groups, the malignant pancreatic/hepatobiliary tumor group, and the healthy control group (all P < 0.05), and the Sjogren's syndrome group had a significantly lower serum IgG4 level than the healthy control group (Z=2.958, P < 0.05). With serum IgG4 ≥1.35 g/L and IgG4 ≥2.01 g/L as the cut-off values, the IgG4-PHD group had a significantly higher positive rate than the non-IgG4-RD autoimmune disease group and the healthy control group (all P < 0.05). The ROC curve analysis showed that IgG4 had an area under the ROC curve of 0.980 in the differential diagnosis of IgG4-PHD and non-IgG4-RD autoimmune diseases, with a sensitivity of 100.00% and a specificity of 94.00% at the optimal cut-off value of 2.21 g/L.  Conclusion  Serum IgG4 level may also increase in non-IgG4-RD autoimmune diseases, while the cut-off value of 2.21 g/L can improve the differential diagnosis of IgG4-PHD and non-IgG4-RD autoimmune diseases, which requires further verification in clinical practice.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    LANZILLOTTA M, MANCUSO G, DELLA-TORRE E. Advances in the diagnosis and management of IgG4 related disease[J]. BMJ, 2020, 369: m1067. DOI: 10.1136/bmj.m1067.
    [2]
    YANG C, LI J, ZHANG YY, et al. Imaging findings of IgG4-related sclerosing mass pancreatitis and analysis of misdiagnosis[J]. Clin Misdiagn Misther, 2021, 305(1): 13-16. DOI: 10.3969/j.issn.1002-3429.2021.01.004.

    杨超, 李进, 张优仪, 等. IgG4相关硬化性肿块型胰腺炎影像学表现及误诊分析[J]. 临床误诊误治, 2021, 305(1): 13-16. DOI: 10.3969/j.issn.1002-3429.2021.01.004.
    [3]
    DELLA-TORRE E, LANZILLOTTA M, DOGLIONI C. Immunology of IgG4-related disease[J]. Clin Exp Immunol, 2015, 181(2): 191-206. DOI: 10.1111/cei.12641.
    [4]
    WALLACE ZS, ZHANG Y, PERUGINO CA, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross- sectional cohorts[J]. Ann Rheum Dis, 2019, 78(3): 406-412. DOI: 10.1136/annrheumdis-2018-214603.
    [5]
    LANZILLOTTA M, CAMPOCHIARO C, MANCUSO G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes[J]. Rheumatology (Oxford), 2020, 59(9): 2435-2442. DOI: 10.1093/rheumatology/keaa221.
    [6]
    MILOSLAVSKY EM, NADEN RP, BIJLSMA JW, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis[J]. Ann Rheum Dis, 2017, 76(3): 543-546. DOI: 10.1136/annrheumdis-2016-210002.
    [7]
    GHAZALE A, CHARI ST, ZHANG L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy[J]. Gastroenterology, 2008, 134(3): 706-715. DOI: 10.1053/j.gastro.2007.12.009.
    [8]
    OTSUKI M, CHUNG JB, OKAZAKI K, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea Symposium on Autoimmune Pancreatitis[J]. J Gastroenterol, 2008, 43(6): 403-408. DOI: 10.1007/s00535-008-2205-6.
    [9]
    WALLACE ZS, NADEN RP, CHARI S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease[J]. Ann Rheum Dis, 2020, 79(1): 77-87. DOI: 10.1136/annrheumdis-2019-216561.
    [10]
    ZHANG DH, ZHAO J. Pathogenesis of immunoglobulin G4-related hepatobiliary and pancreatic diseases[J]. J Clin Hepatol, 2019, 35(6): 1401-1405. DOI: 10.3969/j.issn.1001-5256.2019.06.050.

    张德华, 赵婕. IgG4相关性肝胆胰疾病的发病机制[J]. 临床肝胆病杂志, 2019, 35(6): 1401-1405. DOI: 10.3969/j.issn.1001-5256.2019.06.050.
    [11]
    OKAZAKI K, UCHIDA K, IKEURA T, et al. Current concept and diagnosis of IgG4-related disease in the hepato-bilio-pancreatic system[J]. J Gastroenterol, 2013, 48(3): 303-314. DOI: 10.1007/s00535-012-0744-3.
    [12]
    TANAKA A. IgG4-related sclerosing cholangitis and primary sclerosing cholangitis[J]. Gut Liver, 2019, 13(3): 300-307. DOI: 10.5009/gnl18085.
    [13]
    XU WL, LING YC, WANG ZK, et al. Diagnostic performance of serum IgG4 level for IgG4-related disease: A meta-analysis[J]. Sci Rep, 2016, 6(2): 32035. DOI: 10.1038/srep32035.
    [14]
    KHOSROSHAHI A, WALLACE ZS, CROWE JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol, 2015, 67(7): 1688-1699. DOI: 10.1002/art.39132.
    [15]
    BERNASCONI L, MUNDWILER E, REGENASS S, et al. Variable and inaccurate serum IgG4 levels resulting from lack of standardization in IgG subclass assay calibration[J]. Clin Chem Lab Med, 2019, 57(11): 1777-1783. DOI: 10.1515/cclm-2019-0261.
    [16]
    TANG J, CAI S, YE C, et al. Biomarkers in IgG4-related disease: A systematic review[J]. Semin Arthritis Rheum, 2020, 50(2): 354-359. DOI: 10.1016/j.semarthrit.2019.06.018.
    [17]
    VALENZUELA NM, SCHAUB S. The biology of IgG subclasses and their clinical relevance to transplantation[J]. Transplantation, 2018, 102(1S Suppl 1): S7-S13. DOI: 10.1097/TP.0000000000001816.
    [18]
    USAMI Y, SUGANO M, UEHARA T, et al. Cut-off values of serum IgG4 among three reagents, including a novel IgG4 reagent: A multicenter study[J]. Sci Rep, 2021, 11(1): 7280. DOI: 10.1038/s41598-021-86024-5.
    [19]
    ZEGERS I, KELLER T, SCHREIBER W, et al. Characterization of the new serum protein reference material ERM-DA470k/IFCC: Value assignment by immunoassay[J]. Clin Chem, 2010, 56(12): 1880-1888. DOI: 10.1373/clinchem.2010.148809.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (481) PDF downloads(50) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return